Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NLS Pharmaceutics Ltd. - Warrant
(NQ:
NLSPW
)
0.0179
UNCHANGED
Last Price
Updated: 3:17 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NLS Pharmaceutics Ltd. - Warrant
< Previous
1
2
3
4
Next >
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
March 31, 2025
Via
ACCESS Newswire
NLS Pharmaceutics CEO Issues Letter to Shareholders
December 11, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders
December 03, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
November 18, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
October 28, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
October 15, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
September 25, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces Registered Direct Offering
June 28, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
June 27, 2024
Via
ACCESSWIRE
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
June 25, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
June 11, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
May 28, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
May 24, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
April 19, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
March 22, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
March 20, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
March 20, 2024
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
March 14, 2024
Via
ACCESSWIRE
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
March 11, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
February 23, 2024
Via
ACCESSWIRE
Notice of Deficiency with Nasdaq Continued Listing Requirements
January 12, 2024
Via
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
December 29, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
December 01, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Election of Additional Board Members
November 28, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
November 27, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
November 16, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
October 25, 2023
Via
ACCESSWIRE
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
October 19, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
October 12, 2023
Via
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
August 28, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
